Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER-Positive, HER2-Negative Breast Cancer”

367 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 367 results

Testing effectiveness (Phase 2)WithdrawnNCT03326258
What this trial is testing

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB Positive+15 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT03839823
What this trial is testing

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 222
Testing effectiveness (Phase 2)UnknownNCT02681562
What this trial is testing

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Istituti Ospitalieri di Cremona 45
Not applicableStudy completedNCT04276272
What this trial is testing

D4 Choline Breast PET/CT

Who this might be right for
HER2-negative Breast CancerER Positive Breast CancerMetastatic Breast Cancer
Imperial College London 6
Testing effectiveness (Phase 2)Study completedNCT02732119
What this trial is testing

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 104
Testing effectiveness (Phase 2)WithdrawnNCT03377101
What this trial is testing

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeProgesterone Receptor Positive+1 more
National Cancer Institute (NCI)
Early research (Phase 1)Looking for participantsNCT04360941
What this trial is testing

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerLocally Advanced Breast CancerRecurrent Breast Cancer+3 more
Royal Marsden NHS Foundation Trust 45
Not applicableUnknownNCT02627703
What this trial is testing

(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer

Who this might be right for
Breast Cancer
British Columbia Cancer Agency 80
Early research (Phase 1)Study completedNCT04568902
What this trial is testing

Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Eisai Co., Ltd. 33
Testing effectiveness (Phase 2)WithdrawnNCT01612910
What this trial is testing

Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery

Who this might be right for
Breast Cancer Female
Barbara Ann Karmanos Cancer Institute
Testing effectiveness (Phase 2)Looking for participantsNCT05386108
What this trial is testing

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Who this might be right for
Breast NeoplasmsBrain NeoplasmsNeoplasms by Site+5 more
Stemline Therapeutics, Inc. 73
Not applicableLooking for participantsNCT03723928
What this trial is testing

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu Negative+3 more
SWOG Cancer Research Network 739
Not applicableLooking for participantsNCT07214532
What this trial is testing

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Who this might be right for
Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc. 725
Not applicableActive Not RecruitingNCT04118192
What this trial is testing

NOSTRA-Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer

Who this might be right for
Breast Cancer
University of Birmingham 72
Post-approval studies (Phase 4)Active Not RecruitingNCT05486182
What this trial is testing

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
GE Healthcare 153
Early research (Phase 1)Study completedNCT01009437
What this trial is testing

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

Who this might be right for
Breast Cancer
Masonic Cancer Center, University of Minnesota 28
Large-scale testing (Phase 3)Active Not RecruitingNCT02488967
What this trial is testing

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Who this might be right for
Breast AdenocarcinomaEstrogen Receptor NegativeHER2/Neu Negative+7 more
NRG Oncology 782
Large-scale testing (Phase 3)Active Not RecruitingNCT01805271
What this trial is testing

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Who this might be right for
Primary Non-metastatic Breast CancerWho Remain Disease-free
UNICANCER 1,278
Not applicableLooking for participantsNCT07262138
What this trial is testing

Active Surveillance in Older Women With ER+ Breast Cancer

Who this might be right for
Early Stage Estrogen Receptor (ER) Positive Breast Cancer
University of Pittsburgh 50
Testing effectiveness (Phase 2)Study completedNCT01037790
What this trial is testing

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Who this might be right for
Adult Solid TumorAdenocarcinoma of the ColonAdenocarcinoma of the Rectum+36 more
Abramson Cancer Center at Penn Medicine 304
Load More Results